An experimental skin cancer patch has reached a key regulatory step, with the FDA agreeing to meet with Medicus Pharma to discuss potentially fast-tracking development of its microneedle drug delivery system for basal cell carcinoma.

The company announced that more than three-quarters of patients have already been enrolled in its phase 2 trial testing the microneedle skin patch containing doxorubicin, a long-used chemotherapy. Medicus expects to hear back from the agency before the end of September on next steps, which could include moving more quickly toward pivotal testing.

The American Cancer Society estimates that about 5.4 million cases of basal and squamous cell skin cancers are diagnosed in the United States each year, with basal cell carcinoma making up roughly 80% of these c

See Full Page